CBD, short for cannabidiol, is a compound from cannabis that does not cause a high. Human research is strongest for a purified prescription CBD medicine in certain rare seizure disorders; studies of sleep, oral discomfort, exercise recovery, and other common reasons people try CBD are smaller, mixed, or still early.
CBD is not the same as THC. The CDC’s CBD overview says CBD is not impairing, while THC is the cannabis compound associated with a high. Feeling sleepy, having diarrhea, or noticing a change in appetite can still happen with CBD.
CBD quick facts
| Question | What human research and official guidance say |
|---|---|
| Forms | Consumer products include oils, capsules, foods, lotions, and cosmetics. Studies in this guide used oral, topical, or intraoral forms. |
| Doses researchers used | Examples include 10 or 20 mg/kg per day for 14 weeks in seizure trials, 25–175 mg/day in one sleep/anxiety clinic report, and one 300 mg dose in a healthy-adult sleep study. |
| Typical study length | It varies by question: seizure trials described in a neurological review ran 14 weeks; one sleep study measured effects after a single dose. |
| Main studied uses | Rare seizure disorders, oral pain and inflammation, sleep, exercise performance and recovery, and CBD taken with THC. |
| Does CBD cause a high? | No. CBD itself is not impairing, according to the CDC. Products may contain THC, so read the label carefully. |
| Is CBD legal everywhere? | No. The CDC says hemp-derived CBD may be legal federally, but state rules differ. |
Study results are easier to judge when you know whether they came from a small trial, a randomized trial, or a review of many studies. Evaluating evidence quality explains why that difference matters.
What do human studies show about CBD?
Rare seizure disorders have the strongest evidence
The clearest human evidence concerns purified prescription CBD used alongside seizure medicines for specific rare seizure disorders. The CDC says the FDA approved this medicine for rare seizure disorders. A 2026 systematic review included 57 studies across 37 developmental and treatment-resistant epilepsy groups, involving 971 people. Most were case reports or small case series, but 47 studies reported seizure-frequency reductions in at least one participant. The review describes this as support for future studies in these other epilepsy groups, rather than a result that applies to every type of seizure or every CBD product.
A 2023 neurological review describes randomized trials in Dravet and Lennox-Gastaut syndromes that used oral CBD at 10 or 20 mg/kg per day for 14 weeks alongside existing seizure medicines. It reported greater reductions in convulsive seizures in the CBD groups than in placebo groups. This research concerns a specific oral, purified medicine and supervised care, not a general CBD product.
Oral pain and inflammation research is promising but small
A 2025 systematic review in the Journal of the American Dental Association found seven clinical studies: six randomized trials and one nonrandomized study. Topical and intraoral CBD formulations were associated with reductions in measures including pain, muscle tension, gum inflammation, bacterial load, and aphthous-ulcer symptoms. The researchers could not pool the results because the doses, forms, follow-up periods, and outcomes differed. They called for standardized, long-term trials.
Exercise performance and recovery findings are limited
A 2024 systematic review included seven studies in healthy, physically active people. It found limited favorable findings for measures such as oxygen use and mean power, while evidence for strength measures and post-exercise recovery was limited. The review also called for more safety research across different CBD protocols. That means CBD has been studied for recovery, but the available findings do not establish a dependable result for a particular workout goal.
Sleep findings conflict
A 2021 review of consumer CBD research describes a clinical report of 72 people with sleep or anxiety concerns: 48 had improved sleep scores in the first month while using 25–175 mg/day. The same review describes a randomized, double-blind, placebo-controlled crossover study of 70 healthy people in which a single 300 mg dose had no acute effect on the sleep-wake cycle. Different populations, doses, and study designs make these results hard to combine. Sleep is a good example of why a study result should not be treated as a guarantee for every product or person.
CBD can change THC exposure when they are taken together
A 2026 systematic review and meta-analysis combined 14 acute-dose studies with 341 participants. It found higher average THC exposure and higher levels of THC’s active metabolite when CBD and THC were given together than when THC was given alone. The certainty for the THC finding was very low, while certainty for the metabolite findings was medium. This matters if a product contains both cannabinoids: CBD does not make THC exposure irrelevant.
What doses have researchers studied?
These are study doses, not personal dosing instructions. CBD research uses different forms, populations, and goals, so a number from one study cannot simply be carried over to another form or use.
| Research setting | Form and dose researchers used | Duration or outcome measured |
|---|---|---|
| Dravet and Lennox-Gastaut seizure trials | Oral CBD, 10 or 20 mg/kg/day | 14 weeks |
| Sleep/anxiety clinic report | CBD, 25–175 mg/day | Sleep scores during the first month |
| Healthy-adult sleep study | Single 300 mg dose | Acute sleep-wake effects |
| Oral-disorder studies | Topical and intraoral CBD forms | Doses and follow-up differed across seven studies |
If a label’s claims sound larger than the human study behind them, use ingredient evidence vs marketing claims to separate the ingredient’s research from the product’s promises.
What are CBD side effects and medicine interactions?
The CDC lists possible liver damage, interference with other medicines, drowsiness or sleepiness, diarrhea or appetite changes, and mood changes such as irritability. It also says CBD use during pregnancy is not recommended, and that effects during breastfeeding are not known.
CBD can make alertness and coordination harder for some people. WebMD lists diarrhea, vomiting, loss of appetite, sleepiness, trouble sleeping, and possible liver damage among effects reported with CBD by mouth. It also notes that alcohol may increase drowsiness and liver-damage risk.
Do not treat a CBD product as separate from your medicine list. WebMD specifically flags clobazam, valproate products, other seizure medicines, and medicines that cause dizziness or sleepiness as medicines to discuss before using CBD by mouth. The 2026 CBD-and-THC review adds another reason to check: taking CBD with THC may raise exposure to THC and its active metabolite.
Who should talk to a clinician before using CBD?
- Anyone who is pregnant, breastfeeding, or planning pregnancy.
- Anyone taking prescription or over-the-counter medicines, vitamins, herbs, or other supplements.
- Anyone using seizure medicine, medicines that can cause sleepiness or dizziness, or a product that also contains THC.
- Anyone with a history of liver problems or symptoms that could suggest liver trouble.
Bring the exact product label and your complete medicine list. CBD should not replace a prescribed medicine, and it is not a reason to start, stop, or change one without a clinician’s direction.
What is still unknown about CBD?
Many of the “surprising benefits” discussed online, including broad claims about anxiety, mood, brain health, heart effects, sleep, pain, and women’s health, do not yet have equally strong human evidence. The 2021 consumer-products review says support for many consumer-reported benefits remains limited, and that long-term daily use, product quality, and safe intake levels still need more research.
CBD’s effect on the brain is also not one simple feeling. It does not produce THC’s high, but drowsiness, sleepiness, irritability, and medicine interactions can affect how you feel. A product containing THC may feel different from CBD alone. If you have an immediate dangerous reaction after a THC- or CBD-containing product, the CDC directs people to Poison Control at 1-800-222-1222, 911, or emergency care.
How do you read a CBD label?
Start with the amount. Look for the CBD amount per serving and the total amount in the container, then compare that with the serving size. Next, identify the form: oil, capsule, food, topical product, or another format.
Check whether THC is listed. The CDC cautions that businesses selling hemp and CBD products may also sell THC-containing products, and THC can change both effects and interaction questions. If the label uses a proprietary blend, look for the amount of CBD listed separately; a combined blend total does not tell you the amount of each ingredient. Before using a product with an unclear label or a medicine-interaction concern, ask the seller or a pharmacist for the specific product information.
By ClinicalStudyConnect.com Research Desk